Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Current Leases (2020 - 2026)

Nautilus Biotechnology has reported Current Leases over the past 7 years, most recently at $3.9 million for Q1 2026.

  • Quarterly results put Current Leases at $3.9 million for Q1 2026, down 9.19% from a year ago — trailing twelve months through Mar 2026 was $3.9 million (down 9.19% YoY), and the annual figure for FY2025 was $3.8 million, down 6.47%.
  • Current Leases reached $3.9 million in Q1 2026 per NAUT's latest filing, up from $3.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $4.2 million in Q1 2025 and bottomed at $1.5 million in Q1 2022.
  • Median Current Leases over the past 5 years was $3.7 million (2024), compared with a mean of $3.3 million.
  • The largest annual shift saw Current Leases soared 419.75% in 2022 before it decreased 9.19% in 2026.
  • Over 5 years, Current Leases stood at $2.0 million in 2022, then soared by 77.7% to $3.5 million in 2023, then rose by 15.8% to $4.1 million in 2024, then decreased by 6.47% to $3.8 million in 2025, then increased by 0.52% to $3.9 million in 2026.
  • Business Quant data shows Current Leases for NAUT at $3.9 million in Q1 2026, $3.8 million in Q4 2025, and $4.2 million in Q3 2025.